Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megaxia in locally advanced NSCLC chemoradiotherapy
NCT07150663Phase 3Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of megestrol in cancer anorexia-cachexia syndrome (CACS), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Aug 2025; status: recruiting.
02
Drugs
megestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT07150663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150663.